{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T12:29:05Z","timestamp":1776860945810,"version":"3.51.2"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2019,11,11]],"date-time":"2019-11-11T00:00:00Z","timestamp":1573430400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,11,11]],"date-time":"2019-11-11T00:00:00Z","timestamp":1573430400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Z Rheumatol"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1007\/s00393-019-00723-z","type":"journal-article","created":{"date-parts":[[2019,11,11]],"date-time":"2019-11-11T13:03:23Z","timestamp":1573477403000},"page":"967-978","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Raynaud-Ph\u00e4nomen","Raynaud\u2019s phenomenon"],"prefix":"10.1007","volume":"78","author":[{"given":"C.","family":"Drerup","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Maier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Ehrchen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,11,11]]},"reference":[{"key":"723_CR1","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1024\/0301-1526\/a000661","volume":"46","author":"J Belch","year":"2017","unstructured":"Belch\u00a0J, Carlizza\u00a0A, Carpentier\u00a0PH et\u00a0al (2017) ESVM guidelines\u2014the diagnosis and management of Raynaud\u2019s phenomenon. VASA 46:413\u2013423","journal-title":"VASA"},{"key":"723_CR2","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1056\/NEJMra1507638","volume":"375","author":"FM Wigley","year":"2016","unstructured":"Wigley\u00a0FM, Flavahan\u00a0NA (2016) Raynaud\u2019s phenomenon. N\u00a0Engl J Med 375:556\u2013565","journal-title":"N Engl J Med"},{"key":"723_CR3","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.berh.2016.04.001","volume":"30","author":"M Hughes","year":"2016","unstructured":"Hughes\u00a0M, Herrick\u00a0AL (2016) Raynaud\u2019s phenomenon. Best practice & research. Baillieres Clin Rheumatol 30:112\u2013132","journal-title":"Baillieres Clin Rheumatol"},{"key":"723_CR4","doi-asserted-by":"publisher","first-page":"e006389","DOI":"10.1136\/bmjopen-2014-006389","volume":"5","author":"R Garner","year":"2015","unstructured":"Garner\u00a0R, Kumari\u00a0R, Lanyon\u00a0P et al (2015) Prevalence, risk factors and associations of primary Raynaud\u2019s phenomenon: systematic review and meta-analysis of observational studies. BMJ Open 5:e6389","journal-title":"BMJ Open"},{"key":"723_CR5","doi-asserted-by":"publisher","first-page":"438","DOI":"10.3389\/fphar.2016.00438","volume":"7","author":"MM Fardoun","year":"2016","unstructured":"Fardoun\u00a0MM, Nassif\u00a0J, Issa\u00a0K et\u00a0al (2016) Raynaud\u2019s phenomenon: a brief review of the underlying mechanisms. Front Pharmacol 7:438","journal-title":"Front Pharmacol"},{"key":"723_CR6","doi-asserted-by":"publisher","first-page":"2087","DOI":"10.1136\/annrheumdis-2013-203716","volume":"73","author":"T Minier","year":"2014","unstructured":"Minier\u00a0T, Guiducci\u00a0S, Bellando-Randone\u00a0S et al (2014) Preliminary analysis of the very early diagnosis of systemic sclerosis (VEDOSS) EUSTAR multicentre study: evidence for puffy fingers as a\u00a0pivotal sign for suspicion of systemic sclerosis. Ann Rheum Dis 73:2087\u20132093","journal-title":"Ann Rheum Dis"},{"key":"723_CR7","doi-asserted-by":"publisher","first-page":"3902","DOI":"10.1002\/art.24038","volume":"58","author":"M Koenig","year":"2008","unstructured":"Koenig\u00a0M, Joyal\u00a0F, Fritzler\u00a0MJ et al (2008) Autoantibodies and microvascular damage are independent predictive factors for the progression of Raynaud\u2019s phenomenon to systemic sclerosis: a\u00a0twenty-year prospective study of 586 patients, with validation of proposed criteria for early systemic sclerosis. Arthritis Rheum 58:3902\u20133912","journal-title":"Arthritis Rheum"},{"key":"723_CR8","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1007\/s00393-013-1196-8","volume":"72","author":"B Maurer","year":"2013","unstructured":"Maurer\u00a0B (2013) Early symptoms of dermatomyositis and antisynthetase syndrome. Z\u00a0Rheumatol 72:970\u2013976","journal-title":"Z Rheumatol"},{"key":"723_CR9","doi-asserted-by":"publisher","first-page":"3039","DOI":"10.1007\/s00296-011-2109-2","volume":"32","author":"S Pavlov-Dolijanovic","year":"2012","unstructured":"Pavlov-Dolijanovic\u00a0S, Damjanov\u00a0NS, Stojanovic\u00a0RM et al (2012) Scleroderma pattern of nailfold capillary changes as predictive value for the development of a\u00a0connective tissue disease: a\u00a0follow-up study of 3,029 patients with primary Raynaud\u2019s phenomenon. Rheumatol Int 32:3039\u20133045","journal-title":"Rheumatol Int"},{"key":"723_CR10","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1136\/annrheumdis-2016-209909","volume":"76","author":"O Kowal-Bielecka","year":"2017","unstructured":"Kowal-Bielecka\u00a0O, Fransen\u00a0J, Avouac\u00a0J et al (2017) Update of EULAR recommendations for the treatment of systemic sclerosis. Ann Rheum Dis 76:1327\u20131339","journal-title":"Ann Rheum Dis"},{"key":"723_CR11","doi-asserted-by":"publisher","first-page":"1962","DOI":"10.1136\/annrheumdis-2012-201536","volume":"72","author":"LK Hummers","year":"2013","unstructured":"Hummers\u00a0LK, Dugowson\u00a0CE, Dechow\u00a0FJ et al (2013) A multi-centre, blinded, randomised, placebo-controlled, laboratory-based study of MQX-503, a\u00a0novel topical gel formulation of nitroglycerine, in patients with Raynaud phenomenon. Ann Rheum Dis 72:1962\u20131967","journal-title":"Ann Rheum Dis"},{"key":"723_CR12","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.cd000467.pub2","author":"F Rirash","year":"2017","unstructured":"Rirash\u00a0F, Tingey\u00a0PC, Harding\u00a0SE et\u00a0al (2017) Calcium channel blockers for primary and secondary Raynaud\u2019s phenomenon. Cochrane Database Syst Rev. https:\/\/doi.org\/10.1002\/14651858.cd000467.pub2","journal-title":"Cochrane Database Syst Rev"},{"key":"723_CR13","doi-asserted-by":"publisher","first-page":"1696","DOI":"10.1136\/annrheumdis-2012-202836","volume":"72","author":"M Roustit","year":"2013","unstructured":"Roustit\u00a0M, Blaise\u00a0S, Allanore\u00a0Y et al (2013) Phosphodiesterase\u20115 inhibitors for the treatment of secondary Raynaud\u2019s phenomenon: systematic review and meta-analysis of randomised trials. Ann Rheum Dis 72:1696\u20131699","journal-title":"Ann Rheum Dis"},{"key":"723_CR14","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1136\/annrheumdis-2014-207001","volume":"75","author":"E Hachulla","year":"2016","unstructured":"Hachulla\u00a0E, Hatron\u00a0PY, Carpentier\u00a0P et al (2016) Efficacy of sildenafil on ischaemic digital ulcer healing in systemic sclerosis: the placebo-controlled SEDUCE study. Ann Rheum Dis 75:1009\u20131015","journal-title":"Ann Rheum Dis"},{"key":"723_CR15","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1093\/rheumatology\/40.9.1038","volume":"40","author":"B Coleiro","year":"2001","unstructured":"Coleiro\u00a0B, Marshall\u00a0SE, Denton\u00a0CP et\u00a0al (2001) Treatment of Raynaud\u2019s phenomenon with the selective serotonin reuptake inhibitor fluoxetine. Rheumatology (Oxford) 40:1038\u20131043","journal-title":"Rheumatology (Oxford)"},{"key":"723_CR16","doi-asserted-by":"publisher","first-page":"2646","DOI":"10.1002\/1529-0131(199912)42:12<2646::AID-ANR21>3.0.CO;2-T","volume":"42","author":"M Dziadzio","year":"1999","unstructured":"Dziadzio\u00a0M, Denton\u00a0CP, Smith\u00a0R et al (1999) Losartan therapy for Raynaud\u2019s phenomenon and scleroderma: clinical and biochemical findings in a\u00a0fifteen-week, randomized, parallel-group, controlled trial. Arthritis Rheum 42:2646\u20132655","journal-title":"Arthritis Rheum"},{"key":"723_CR17","doi-asserted-by":"publisher","first-page":"1906","DOI":"10.1093\/rheumatology\/kew224","volume":"55","author":"CP Denton","year":"2016","unstructured":"Denton\u00a0CP, Hughes\u00a0M, Gak\u00a0N et\u00a0al (2016) BSR and BHPR guideline for the treatment of systemic sclerosis. Rheumatology 55:1906\u20131910","journal-title":"Rheumatology"},{"key":"723_CR18","first-page":"503","volume":"19","author":"R Scorza","year":"2001","unstructured":"Scorza\u00a0R, Caronni\u00a0M, Mascagni\u00a0B et al (2001) Effects of long-term cyclic iloprost therapy in systemic sclerosis with Raynaud\u2019s phenomenon. A randomized, controlled study. Clin Exp Rheumatol 19:503\u2013508","journal-title":"Clin Exp Rheumatol"},{"key":"723_CR19","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1007\/s00105-003-0578-2","volume":"54","author":"G Bali","year":"2003","unstructured":"Bali\u00a0G, Aberer\u00a0E (2003) Iloprost therapy in systemic sclerosis. Hautarzt 54:845\u2013851","journal-title":"Hautarzt"},{"key":"723_CR20","first-page":"381","volume":"15","author":"S Ceru","year":"1997","unstructured":"Ceru\u00a0S, Pancera\u00a0P, Sansone\u00a0S et al (1997) Effects of five-day versus one-day infusion of iloprost on the peripheral microcirculation in patients with systemic sclerosis. Clin Exp Rheumatol 15:381\u2013385","journal-title":"Clin Exp Rheumatol"}],"container-title":["Zeitschrift f\u00fcr Rheumatologie"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-019-00723-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00393-019-00723-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-019-00723-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,10]],"date-time":"2020-11-10T00:57:59Z","timestamp":1604969879000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00393-019-00723-z"}},"subtitle":["Praktisches Management","Practical management"],"short-title":[],"issued":{"date-parts":[[2019,11,11]]},"references-count":20,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["723"],"URL":"https:\/\/doi.org\/10.1007\/s00393-019-00723-z","relation":{},"ISSN":["0340-1855","1435-1250"],"issn-type":[{"value":"0340-1855","type":"print"},{"value":"1435-1250","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,11,11]]},"assertion":[{"value":"11 November 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"Gem\u00e4\u00df den Richtlinien des Springer Medizin Verlags werden Autoren und Wissenschaftliche Leitung im Rahmen der Manuskripterstellung und Manuskriptfreigabe aufgefordert, eine vollst\u00e4ndige Erkl\u00e4rung zu ihren finanziellen und nichtfinanziellen Interessen abzugeben.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"<b>C.\u00a0Drerup<\/b>: Finanzielle Interessen: C.\u00a0Drerup gibt an, dass kein finanzieller Interessenkonflikt besteht. Nichtfinanzielle Interessen: Assistenzarzt Hautklinik Universit\u00e4tsklinikum M\u00fcnster. <b>A.\u00a0Maier<\/b>: Finanzielle Interessen: Honorare und Fortbildungsunterst\u00fctzung von: AbbVie, BMS, Chugai, Janssen, medac, MSD, Novartis, Pfizer, UCB. Nichtfinanzielle Interessen: Ober\u00e4rztin in der Klinik f\u00fcr Rheumatologie, St.\u00a0Josef-Stift Sendenhorst, Rheumatologisches Kompetenzzentrum Nordwestdeutschland, Sendenhorst\u00a0| Mitgliedschaft: Deutsche Gesellschaft f\u00fcr Rheumatologie (DGRh). <b>J.\u00a0Ehrchen<\/b>: Finanzielle Interessen: Honorare f\u00fcr Vortragst\u00e4tigkeiten von den Firmen: Actelion, Boehringer, Sobi, LaRoche Posay, Mylan, Galderma, Novartis, Pfizer, Chugai. Nichtfinanzielle Interessen: Facharzt f\u00fcr Haut- und Geschlechtskrankheiten und Oberarzt an der Klinik f\u00fcr Hautkrankheiten, Allgemeine Dermatologie und Venerologie, M\u00fcnster\u00a0| Leitung des Bereiches Autoimmunerkrankungen an der Klinik f\u00fcr Hautkrankheiten\u00a0| Mitgliedschaft: Deutsches Netzwerk f\u00fcr Systemische Sklerose (DNSS).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Autoren"}},{"value":"Die vollst\u00e4ndige Erkl\u00e4rung zum Interessenkonflikt der Wissenschaftlichen Leitung finden Sie am Kurs der zertifizierten Fortbildung auf .","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Wissenschaftliche Leitung"}},{"value":"erkl\u00e4rt, dass f\u00fcr die Publikation dieser CME-Fortbildung keine Sponsorengelder an den Verlag flie\u00dfen.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Der Verlag"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autoren keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien. F\u00fcr Bildmaterial oder anderweitige Angaben innerhalb des Manuskripts, \u00fcber die Patienten zu identifizieren sind, liegt von ihnen und\/oder ihren gesetzlichen Vertretern eine schriftliche Einwilligung vor.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Der Verlag"}}]}}